🤖 OpenMed - AI Token Usage and Applications
This article details OpenMed's substantial AI token consumption and its application across development and data platforms. The company processes billions of tokens daily for various operational tasks.
Key Points:
• OpenMed processed approximately 20 billion tokens since March.
• Daily token usage averaged about 1 billion, with a peak of 2.4 billion using GPT-5.6 Sol ULTRA.
• AI skills are applied to GitHub for reviewing issues and pull requests.
• AI also organizes models and datasets on Hugging Face.
🔗 Resources:
• OpenMed_AI ↗ - Company on X
• Hugging Face ↗ - AI community and platform
Image
✨ SubtleMedical - Medical Imaging Improvements
SubtleMedical will attend the FRS & FRBMA conference to discuss improvements in medical imaging. The company focuses on methods to enhance image quality and increase patient capacity.
Key Points:
• SubtleMedical aims to improve medical image quality.
• The company also seeks to increase patient capacity in medical diagnostics.
• They will be present at FRS & FRBMA in Orlando from July 17-19, 2026.
🔗 Resources:
• SubtleMedical ↗ - Company on X
• Schedule Meeting ↗ - Schedule a meeting with experts
Image
💡 Longevity - A Coordination Problem
Achieving longevity is framed as a coordination challenge that integrates multiple components within the health sector. This involves connecting people, data, AI, research, incentives, and access to healthcare.
Key Points:
• Longevity outcomes depend on coordinating various elements.
• Key elements include people, data, and AI.
• Research, incentives, and access also contribute to the coordination challenge.
🔗 Resources:
• Rejuve_AI ↗ - Organization on X
Image
🤖 Precigenetics - Volumetric Label-Free Imaging
This post introduces Precigenetics, a company developing volumetric label-free imaging technology. This method avoids phototoxicity, offering a different approach to biological analysis.
Key Points:
• Precigenetics specializes in volumetric label-free imaging.
• The technology operates without phototoxicity.
• This imaging method aids in biological decision-making.
🔗 Resources:
• Precigenetics ↗ - Biotech company
• Andercot ↗ - Angel investor
Image
🚀 Proscia - Concentriq Fifth Generation
Proscia is announcing the fifth generation of Concentriq with an upcoming webinar. This release aims to modernize case review by providing intelligence support for pathologists and lab leaders.
Key Points:
• Proscia will release the Fifth Generation of Concentriq.
• A webinar on July 28 will demonstrate its features.
• The update supports pathologists and lab leaders in case review.
• It integrates clinically informed intelligence into decision workflows.
🔗 Resources:
• Proscia ↗ - Digital pathology company
Image
💡 DeSci - Biotech Funding Alternatives
The discussion centers on DeSci (Decentralized Science) as an alternative funding mechanism for biotech ventures. This contrasts with traditional funding models, exemplified by a successful founder exploring new approaches.
Key Points:
• DeSci offers an alternative funding route for biotech companies.
• This approach diverges from traditional capital acquisition methods.
• The case references an entrepreneur who previously sold a company for $300M.
🔗 Resources:
• BioProtocol ↗ - Protocol for biotech
🤖 Valar Labs - AI-Based Biomarker for mHSPC
A new publication discusses an AI-based biomarker for metastatic hormone-sensitive prostate cancer (mHSPC). This biomarker, derived from routine H&E slides, helps identify patients who benefit from treatment intensification.
Key Points:
• A new AI-based biomarker helps identify mHSPC patients.
• The biomarker predicts benefit from treatment intensification with docetaxel.
• It is derived from standard H&E histology slides.
• The findings are published in JCO PO.
🔗 Resources:
• valarlabs ↗ - Biotech company
• tjroycemd ↗ - Doctor and researcher
• Publication ↗ - JCO PO publication
🤖 REZILIENT-1 - Zipalertinib in NSCLC
Dr. Arjan Gower discussed the REZILIENT-1 study, which evaluated zipalertinib in EGFR ex20ins NSCLC. Zipalertinib showed a 40% ORR in previously treated patients without prior ex20ins targeted therapy.
Key Points:
• Zipalertinib demonstrated a 40% objective response rate (ORR) in REZILIENT-1.
• The study focused on previously treated EGFR ex20ins NSCLC patients.
• These patients had not received prior ex20ins targeted therapy.
• UCLA L-13 is testing perioperative zipalertinib in resectable NSCLC.
🔗 Resources:
• KolPulseAI ↗ - AI in healthcare
• DAVAOnc ↗ - Oncology resource
• ArjanGower ↗ - Doctor on X
• UCLA ↗ - University
Image
Image
Image
Image
⭐️ Support
If you liked reading this report, please star ⭐️ this repository and follow me on Github ↗, 𝕏 (previously known as Twitter) ↗ to help others discover these resources and regular updates.
